February 2019 – Israel Biotech Fund

Ayala entered a license agreement with Novartis

February 4th, 2019 by IBF

Ayala entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma.

Biond Bio announced the closing of a $17 million Series B financing

February 4th, 2019 by IBF

The financing and due diligence were led by Israel Biotech Fund and Harel Insurance & Finance Group, with participation of Celgene Corporation, (NASDAQ: CELG), the Japanese-Israeli fund, SBI JI Innovation Fund and existing investors.